Examining the role of metabolites in bioequivalence assessment

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 2, 2010, Pages 198-217

  Karalis, Vangelis ^a   Macheras, Panos ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; DRUG METABOLITE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPARTMENT MODEL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG METABOLISM; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIMULATION;

EID: 78650343186     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j35889     Document Type: Article

References (29)

1. Food and Drug Administration. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. General Consideration, Center for Drug Evaluation and Research (CDER), Rockville, MD, 2000.
2. Houston, J.B. Importance of metabolites in bioequivalence, in McGilveray JJ: Dighe SV: French IW: Midha KK: Skelly JP (eds.), Proceedings Bio-International 89: Issues in the evaluation of bioavailability data. Toronto, Canada, pp 99-100, 1989.
3. Tucker, G., Rostami, A., Jackson, P. Metabolite measurement in bioequivalence studies: Theoretical considerations, in Midha KK: Blume H (eds.), Bio-International: Bioavailability, Bioequivalence and Pharmacokinetics. International Conference of FIP. ''Bio- International'92'', Bad Homburg, Germany, Medpharm Scientific Publishers, Stuttgart, pp 163-170, 1993.
4. A.J. Jackson, G. Robbie, P. Marroum. Metabolites and bioequivalence: past and present. Clin Pharmacokinet, 43:655-672, 2004.
5. K. Midha, M. Rawson, and J. Hubbard. The Role of Metabolites in Bioequivalence. Pharm Res, 21:1331-1344, 2004.
6. K. Midha, V. Shah, G. Singh, R. Patnaik. Conference report: Bio-International 2005. J Pharm Sci, 96:747-754, 2007.
7. Food and Drug Administration. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, 2003.
8. European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Committee for Proprietary Medicinal Products (CPMP), London, 2001.
9. European Medicinal Evaluation Agency. Committee for Medicinal Products for Human Use (CHMP). Concept Paper for an Addendum to the Note for Guidance on the Investigation of Bioavailability and Bioequivalence: Evaluation of Bioequivalence of Highly Variable Drugs and Drug Products. London, 2006.
10. European Medicines Agency, Evaluation of Medicines for Human Use, CHMP efficacy working party) therapeutic subgroup on pharmacokinetics: Questions & Answers on the Bioavailability and Bioequivalence Guideline, London, 2006.
11. I. Mahmood. Assessment of metabolites in bioequivalence studies: should bioequivalence criteria be applied on the sum of parent compound and metabolite? Int J Clin Pharmacol Ther, 36:540-544, 1998.
12. K. Midha, J. Hubbard, G. McKay, E. Hawes, D. Hsia. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8- hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol, 31:177-183, 1993.
13. K. Midha, J. Hubbard, G. McKay, M. Rawson, D. Hsia D. The role of metabolites in a bioequivalence study II: amoxapine, 7- hydroxyamoxapine, and 8-hydroxyamoxapine. Int J Clin Pharmacol Ther, 37:428-438, 1999.
14. V. Hutt, K. Sauter, G. Pabst, R. Bonn, E. Fritschi. Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. Arzneimittelforschung, 44:1317-1321, 1994.
15. W.M. Glazer, L.T. Friedhoff, S.R. Marder, and W.A. Brown. The determination of the steadystate pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection. Schizophr Res, 8:111-117, 1992.
16. H. Mascher, C. Kikuta, A. Millendorfer, H. Schiel, and G. Ludwig. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: Desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Int J Clin Pharm Ther, 35:9-13, 1997.
17. E. Heinonen, M. Anttila, and A. Lammintausta. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharm Therap, 56:742-749, 1994.
18. H. R. Kwon, P. Green, and S. Curry. Pharmacokinetics of nitroglycerin and its metabolites after administration of sustainedrelease tablets. Biopharm Drug Dispos, 13:141- 152, 1992.
19. E. Ezan, T. Ardouin, B. Landes, B. Flouvat, T. Hanslik, J. Legeai, and J. Grognet. Bioequivalence study of alphadihydroergocryptine utility of metabolite evaluation. Int J Clin Pharmacol Ther, 34:32-37, 1996.
20. H. Vergin, G. Mahr, R. Metz, A. Eichinger, V. Nitsche, and H. Martens H. Analysis ofmetabolites - a new approach to bioequivalence studies of spironolactone formulations. Int J Clin Pharmacol Ther, 35:334-340, 1997.
21. M.L. Chen, A.J. Jackson. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm Res, 8:25-32, 1991.
22. M.L. Chen, A.J. Jackson. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect. Pharm Res, 12:700-708, 1995.
23. S. Rosenbaum and J. Lam. Bioequivalence parameters of parent drug and its first-pass metabolite: comparative sensitivity to sources of pharmacokinetic variability. Drug Dev Indust Pharm, 23:337-344, 1997.
24. A.J. Jackson. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect. Pharm Res, 17:1432-1436, 2000.
25. A.C. Braddy, A.J. Jackson. Role of metabolites for drugs that undergo nonlinear first-pass effect: impact on bioequivalency assessment using singledose simulations. J Pharm Sci, 99:515-523, 2010.
26. C. Fernández-Teruel, R. Nalda Molina, I. González-Alvarez, C. Navarro-Fontestad, A. García-Arieta, V.G. Casabó, M. Bermejo. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I). Eur J Pharm Sci, 36:137-146, 2009.
27. C. Fernández-Teruel, I. Gonzalez-Alvarez, C. Navarro-Fontestad, A. García-Arieta, M. Bermejo, V.G. Casabó. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics. Eur J Pharm Sci, 36:147-156, 2009.
28. D.J. Schuirmann. A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm, 15:657- 680, 1987.
29. L. Tothfalusi, S. Speidl, L. Endrenyi. Exposure- response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br J Clin Pharmacol, 65:110-122, 2007.